Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

QR-1123

Gene therapy (AAV vector) · developed by ProQR Therapeutics

Phase 1/2 Most advanced trial
PRQR Developer
1 Registered trials

What is QR-1123?

QR-1123 is an AAV gene therapy in development for autosomal dominant retinitis pigmentosa and other inherited retinal dystrophies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy (AAV vector)
Therapy area
Ophthalmology
Developer
ProQR Therapeutics (PRQR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04123626 Phase 1/2 Autosomal Dominant Retinitis Pigmentosa Active not recruiting PRQR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Autosomal Dominant Retinitis PigmentosaEye DiseasesEye Diseases, HereditaryRetinal DiseaseRetinal DystrophiesRetinitisVision DisordersVision Tunnel

More from ProQR Therapeutics

QR-010 Phase 1/2 QR-421a Phase 1/2 QR-504a Phase 1 Sepofarsen Phase 2/3

Follow PRQR, the company behind QR-1123

See PRQR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PRQR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.